Institute Curie Hospital, First in France to Install TomoTherapy® Hi∙Art® Treatment System
TomoTherapy Incorporated announced today that France’s Institute Curie Hospital has acquired the first TomoTherapy Hi∙Art system to be used in France. The Institute Curie Hospital announced the acquisition with a tour of the treatment area and a reception hosted by Professor Claude Huriet, President of the Institute Curie, on March 7th, 2007. Notable attendees included Professor Dominque Maranchi, President of the National Institute of Cancer (INCA) and Marc Lipinski, Vice President of the Regional Council, IIe-de-France.
A private foundation comprised of France’s largest cancer research center and a leading public hospital, the Institute Curie was founded in 1909 by Marie Curie. Since receiving state approval in 1921, the Institute Curie has made developing innovative and individualized treatments, and ensuring availability of the most advanced techniques, among its chief priorities.
“We are pleased to have the TomoTherapy Hi∙Art system being used by a pioneering institution so notably linked to the field of radiation,” said TomoTherapy Inc. CEO Dr. Fred Robertson.
The decision by the Institute Curie Hospital to install the TomoTherapy Hi∙Art system follows calls for research proposals launched by the National Cancer Institute in July 2005 to promote implementation of image-guided radiation therapy technology that was not previously available in France. Two other centers in France, Nantes and Bordeaux, intend to install the TomoTherapy Hi∙Art system as a result of the proposals’ recommendations.
About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.
26 Mar 2007
| Investor Contact: Thomas E. Powell Chief Financial Officer 608.824.2800 tpowell@tomotherapy.com |
Media Contact: Kevin O’Malley Manager Corporate Communications 608.824.2800 komalley@tomotherapy.com |
